HomeCompareWTFCP vs ABBV

WTFCP vs ABBV: Dividend Comparison 2026

WTFCP yields 6.88% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WTFCP wins by $67.94M in total portfolio value
10 years
WTFCP
WTFCP
● Live price
6.88%
Share price
$25.00
Annual div
$1.72
5Y div CAGR
69.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$68.04M
Annual income
$59,317,756.99
Full WTFCP calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — WTFCP vs ABBV

📍 WTFCP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWTFCPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WTFCP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WTFCP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WTFCP
Annual income on $10K today (after 15% tax)
$584.38/yr
After 10yr DRIP, annual income (after tax)
$50,420,093.44/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, WTFCP beats the other by $50,399,037.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WTFCP + ABBV for your $10,000?

WTFCP: 50%ABBV: 50%
100% ABBV50/50100% WTFCP
Portfolio after 10yr
$34.07M
Annual income
$29,671,264.37/yr
Blended yield
87.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

WTFCP
Analyst Ratings
1
Strong
11
Buy
10
Hold
Consensus: Buy
Altman Z
0.3
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WTFCP buys
0
ABBV buys
0
No recent congressional trades found for WTFCP or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWTFCPABBV
Forward yield6.88%3.06%
Annual dividend / share$1.72$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR69.4%40.6%
Portfolio after 10y$68.04M$102.3K
Annual income after 10y$59,317,756.99$24,771.77
Total dividends collected$67.31M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: WTFCP vs ABBV ($10,000, DRIP)

YearWTFCP PortfolioWTFCP Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,865$1,164.63$11,550$430.00+$315.00WTFCP
2$14,883$2,187.62$13,472$627.96+$1.4KWTFCP
3$20,269$4,344.42$15,906$926.08+$4.4KWTFCP
4$31,055$9,367.20$19,071$1,382.55+$12.0KWTFCP
5$55,950$22,721.61$23,302$2,095.81+$32.6KWTFCP
6$124,677$64,809.79$29,150$3,237.93+$95.5KWTFCP
7$362,044$228,639.92$37,536$5,121.41+$324.5KWTFCP
8$1,438,520$1,051,132.60$50,079$8,338.38+$1.39MWTFCP
9$8,151,348$6,612,131.76$69,753$14,065.80+$8.08MWTFCP
10$68,039,699$59,317,756.99$102,337$24,771.77+$67.94MWTFCP

WTFCP vs ABBV: Complete Analysis 2026

WTFCPStock

Wintrust Financial Corporation operates as a financial holding company. It operates in three segments: Community Banking, Specialty Finance, and Wealth Management. The Community Banking segment offers non-interest bearing deposits, non-brokered interest-bearing transaction accounts, and savings and domestic time deposits; home equity, consumer, and real estate loans; safe deposit facilities; and automatic teller machine (ATM), online and mobile banking, and other services. It also engages in the retail origination and purchase of residential mortgages for sale into the secondary market; and provision of lending, deposits, and treasury management services to condominium, homeowner, and community associations, as well as asset-based lending for middle-market companies. In addition, this segment offers loan and deposit services to mortgage brokerage companies; lending to restaurant franchisees; direct leasing; small business administration loans; commercial mortgages and construction loans; and financial solutions. It provides personal and commercial banking services primarily to individuals, small to mid-sized businesses, local governmental units, and institutional clients. The Specialty Finance segment offers commercial and life insurance premiums financing for businesses and individuals; accounts receivable financing, value-added, and out-sourced administrative services; and other specialty finance services, as well as data processing of payrolls, billing, and cash management services to temporary staffing industry. The Wealth Management segment provides trust and investment, asset management, tax-deferred exchange, securities brokerage, and retirement plan services. The company operates 173 banking facilities and 228 ATMs in the Chicago metropolitan area, southern Wisconsin, northwest Indiana, and Florida. Wintrust Financial Corporation was founded in 1991 and is headquartered in Rosemont, Illinois.

Full WTFCP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this WTFCP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WTFCP vs SCHDWTFCP vs JEPIWTFCP vs OWTFCP vs KOWTFCP vs MAINWTFCP vs JNJWTFCP vs MRKWTFCP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.